Discussion
QRL-201, an experimental therapy from Quralis, slowed disease progression by 50% in people with amyotrophic lateral sclerosis (ALS) who received one of the tested doses of the therapy, according to final results from a Phase 1/2 clinical trial. The findings come from the dose-range finding phase of the…